Vitrolife interim report January - September 2003

· Net sales for the group amounted to SEK 72.3 million (85.5) where 28.5 are assigned to business disposed 2002. Gross margin increased to 64% (52%), the group’s operating result totalled SEK 38.8 million (-12.2).

· Net sales for core activities increased by 27% to a total of SEK 72.3 million (57.0) and gross result increased by 56 % to SEK 46.3 million (29.5), the operating result amounted to SEK 3.7 million (-26.6).

· The group's net result totalled SEK 39.6 million (-8.7).

· Vitrolife sells subsidiaries A-life Ltd and A-life Inc for 60 MSEK plus royalty to Mentor Corp., USA.

· Reduction of the share premium reserve of SEK 292 million settled.

· Result per share amounted to SEK 2.16 (-0.47).

Gothenburg, October 22, 2003.

Vitrolife AB (Publ)

For further information, please contact:

Vitrolife

CEO: Magnus Nilsson

Tel: +46 31 721 80 00

Mobile +46 708 22 80 61

mnilsson@vitrolife.com

CFO and IR agent:

Margareta Fischer

Tel: +46 31 721 80 00

Mobile: +46 708 22 80 13

mfischer@vitrolife.com

Vitrolife is a global biomedical corporation that works with products for cell and tissue technology. The Vitrolife group consists of the parent company, Vitrolife AB (Publ) and two wholly owned subsidiaries: Vitrolife Sweden AB (Gothenburg, Sweden), Vitrolife Inc. (Denver, Colorado). The group’s operations focused on three geographic areas.

• Europe/Middle East

• The Americas

• Rest of the World

Vitrolife’s business concept is to develop, produce and sell advanced products and systems for the preparation, cultivation, preservation and support of cells, tissues and organs.

---